What is the current price for "Will the FDA approve intismeran autogene (V940/mRNA-4157)?"?

The leading outcome "Yes" is currently trading at 95.0% probability.

How many markets are available for "Will the FDA approve intismeran autogene (V940/mRNA-4157)?"?

There are 5 markets available for this event on Kalshi.

What is the trading volume for "Will the FDA approve intismeran autogene (V940/mRNA-4157)?"?

Total trading volume is approximately $2K.

BackKKALSHI

Will the FDA approve intismeran autogene (V940/mRNA-4157)?

Yes95%

Vol$2.02K

Markets5

95%

TradeTrade on Kalshi

Event Group

EventKALSHI

Single EventKALSHIScience and Technology

Will the FDA approve intismeran autogene (V940/mRNA-4157)?

Name: Will the FDA approve intismeran autogene (V940/mRNA-4157)?
Start: 2026-10-12T03:37:03.747Z
End: 2026-11-11T03:37:03.747Z

Part of: Will the FDA approve intismeran autogene (V940/mRNA-4157)?

intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma If the FDA approves intismeran autogene, V940/mRNA-4157, with pembrolizumab, KEYTRUDA, for adjuvant treatment of completely resected stage IIB-IV melanoma for marketing before X 1, 2028, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application, NDA, or Biologics License Application,

YesLeading Yes Probability

95%

VolTotal Volume

$2.02K

Markets

Trade on Kalshi

Will the FDA approve intismeran autogene (V940/mRNA-4157)?

Yes

95%

Vol

$2.02K

Markets

Trade

Market Price Graph

5 markets tracked

Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Jul 1, 2028?

kalshi

No data available

All Markets(5)

Market	Price
Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Jul 1, 2028?	95%
Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Jan 1, 2028?	88%
Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Oct 1, 2027?	65%
Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Jul 1, 2027?	14%
Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Apr 1, 2027?	6%

Markets (5)

Sort

KALSHIHealth

Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Jul 1, 2028?

If the FDA approves intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma for marketing before Jul 1, 2028, then the market resolves to Yes. Secondary rules: An approval is defined as: For new drugs: FDA issuance of an

Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Jan 1, 2028?

If the FDA approves intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma for marketing before Jan 1, 2028, then the market resolves to Yes. Secondary rules: An approval is defined as: For new drugs: FDA issuance of an

Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Oct 1, 2027?

If the FDA approves intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma for marketing before Oct 1, 2027, then the market resolves to Yes. Secondary rules: An approval is defined as: For new drugs: FDA issuance of an

Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Jul 1, 2027?

If the FDA approves intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma for marketing before Jul 1, 2027, then the market resolves to Yes. Secondary rules: An approval is defined as: For new drugs: FDA issuance of an

Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Apr 1, 2027?

If the FDA approves intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma for marketing before Apr 1, 2027, then the market resolves to Yes. Secondary rules: An approval is defined as: For new drugs: FDA issuance of an

Will the FDA approve intismeran autogene (V940/mRNA-4157)?

Will the FDA approve intismeran autogene (V940/mRNA-4157)?

Will the FDA approve intismeran autogene (V940/mRNA-4157)?

Market Price Graph

Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Jul 1, 2028?

Rules & Resolution Criteria

Markets (5)

Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Jul 1, 2028?

Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Jan 1, 2028?

Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Oct 1, 2027?

Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Jul 1, 2027?

Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Apr 1, 2027?

Share This Event